Aptus Clinical announces recruitment has started for COSMIC-19

Alderley Park-based Aptus Clinical Ltd today announced that recruitment has started on the innovative COSMIC-19 study, which they believe will help transform and shape clinical trial monitoring in the future. COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients), sponsored by The Christie NHS Foundation Trust in collaboration with Manchester University Foundation NHS Trust, utilises advanced...

Aptus Clinical and Alderley Park benefit from Northern Powerhouse Investment Fund

The Northern Powerhouse Investment Fund which is delivered by British Business Bank, has invested a total of £2.5m into businesses based at Alderley Park, Cheshire, the UK’s largest single site life science campus. The £2.5m invested into businesses at Alderley Park forms part of NPIF’s £10m milestone that was recently achieved in the Cheshire and...

Design of innovative FiH study: CellCentric

Design of Innovative FiH Study CellCentric Planning a Route ForwardPlanning a First in Human (FiH) study The ChallengeCellCentric approached Aptus Clinical to assist them in designing their First in Human (FiH) study for their lead project, a small molecule inhibitor of p300/CBP The SolutionAptus Clinical convened a multi-disciplinary panel of medical, scientific and technical experts...

Renaissance of interest in medicines modulating ECS: Rising to the challenge

The body’s endocannabinoid system (ECS) consists of receptors and chemical messengers located in the central and peripheral nervous system, forming a biochemical communication network throughout the body that regulates a variety of physiological and cognitive processes. Drugs that modify the activity of endocannabinoids such as cannabinoid receptor agonists and antagonists, agents modifying cannabinoid transport, or...

Aptus Clinical selected as clinical CRO by Artelo Biosciences

Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical...

Development of an operationally feasible clinical pharmacology package

Development of an operationally feasible clinical pharmacology package US Biotech Case Study Development of Pharmacology Programme For Lead Oncology Asset The ChallengeAptus Clinical was asked by a US-based Biotech to assess whether the clinical pharmacology programme for their lead oncology asset could be conducted in healthy volunteers rather than patients The SolutionAn expert panel was...

Scroll to top
Cookie Consent with Real Cookie Banner